Keyphrases
Irinotecan
100%
Metastatic Colorectal Cancer (mCRC)
100%
Tissue Inhibitor of metalloproteinase-1 (TIMP-1)
100%
Carcinoembryonic Antigen
100%
Cetuximab
100%
Confidence Interval
38%
Progression-free Survival
16%
Overall Survival
16%
Wild-type KRAS
11%
Hazard Ratio
11%
Biomarker Studies
11%
Baseline Characteristics
5%
Predictive Role
5%
Indications for Treatment
5%
Survival Analysis
5%
Clinical Characteristics
5%
Standardized Method
5%
Colorectal Cancer
5%
Overall Response Rate
5%
Disease Control
5%
Metalloproteinases
5%
Treatment Level
5%
Clinical Value
5%
Epidermal Growth Factor Receptor
5%
Multivariate Analysis
5%
Randomized Trial
5%
Chemotherapy Resistance
5%
Non-associated
5%
Receptor Regulation
5%
1-measurement
5%
Glycoprotein
5%
Tumor Progression
5%
Blood Samples
5%
Palliative Chemotherapy
5%
Patient's Will
5%
Treatment Efficacy
5%
Median Progression-free Survival
5%
Combination Therapy
5%
Prognostic Value
5%
Epidermal Growth Factor Receptor Inhibitors
5%
Pharmacology, Toxicology and Pharmaceutical Science
Cetuximab
100%
Tissue Inhibitor of Metalloproteinase
100%
Carcinoembryonic Antigen
100%
Metastatic Colorectal Cancer
100%
Irinotecan
100%
Biological Marker
100%
Progression Free Survival
23%
Overall Survival
17%
Combination Therapy
11%
Biomarker Study
11%
Chemotherapy
11%
Tissue Inhibitor of Metalloproteinase 1
5%
Tumor Growth
5%
Diseases
5%
Metalloproteinase
5%
Side Effect
5%
Epidermal Growth Factor Receptor
5%
Glycoprotein
5%
Epidermal Growth Factor Receptor Kinase Inhibitor
5%
Enzyme-Linked Immunosorbent Assay
5%
Primary Tumor
5%
Colorectal Carcinoma
5%
Immunology and Microbiology
Carcinoembryonic Antigen
100%
Cetuximab
100%
Irinotecan
100%
Progression Free Survival
80%
Blood Plasma
80%
Overall Survival
60%
Wild Type
40%
Epidermal Growth Factor
40%
Glycoprotein
20%
ELISA
20%